Research ExplorerPublicationsApplication of multipotent mesenchymal stromal cells in pedi...

Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation

Standard

Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. / Müller, Ingo; Kordowich, Sandra; Holzwarth, Christina; Isensee, Gesa; Lang, Peter; Neunhoeffer, Felix; Dominici, Massimo; Greil, Johann; Handgretinger, Rupert.

In: BLOOD CELL MOL DIS, Vol. 40, No. 1, 18.09.2007, p. 25-32.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Müller, I, Kordowich, S, Holzwarth, C, Isensee, G, Lang, P, Neunhoeffer, F, Dominici, M, Greil, J & Handgretinger, R 2007, 'Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation', BLOOD CELL MOL DIS, vol. 40, no. 1, pp. 25-32. https://doi.org/10.1016/j.bcmd.2007.06.021

APA

Müller, I., Kordowich, S., Holzwarth, C., Isensee, G., Lang, P., Neunhoeffer, F., Dominici, M., Greil, J., & Handgretinger, R. (2007). Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. BLOOD CELL MOL DIS, 40(1), 25-32. https://doi.org/10.1016/j.bcmd.2007.06.021

Vancouver

Müller I, Kordowich S, Holzwarth C, Isensee G, Lang P, Neunhoeffer F et al. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation. BLOOD CELL MOL DIS. 2007 Sep 18;40(1):25-32. https://doi.org/10.1016/j.bcmd.2007.06.021

Bibtex

@article{3a8fe85b52df4fd184cfdfcc8a2567db,
title = "Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation",
abstract = "Multipotent mesenchymal stromal cells (MSC) have immunomodulatory effects. The aim of this study was to demonstrate safety and feasibility of MSC transfusion in pediatric patients who had undergone allogeneic stem cell transplantation from MMFD, MUD, MMUD and MSD. Patients with posttransplant complications based on deregulated immune effector cells who may benefit from an immunomodulatory effect of MSC had been selected. MSC were isolated from the hematopoietic stem cell donors in five cases and from a third party parental donor in two cases. We transfused ex vivo-expanded MSC in 11 doses into seven pediatric patients. Cell doses were escalated based on availability from 0.4x10(6) to 3.0x10(6) per kg bodyweight No adverse effects were detected with a maximum follow-up of 29 months. One out of three patients showed slight improvement of chronic GVHD. Two patients with severe acute GvHD did not progress to cGvHD. One patient received MSC to stabilize graft function after secondary haploidentical transplantation. One patient recovered from trilineage failure due to severe hemophagocytosis. This is the first case of a pediatric patient treated with MSC for trilineage failure after haploidentical stem cell transplantation from her father. We report the first series of 11 transfusions of expanded MSC in pediatric patients with immunological complications after allogeneic transplantation. Transfusion of MSC was safe and encouraging improvements in some patients were observed.",
keywords = "Adolescent, Child, Child, Preschool, Female, Graft Rejection, Graft vs Host Disease, Humans, Male, Mesenchymal Stem Cell Transplantation, Mesenchymal Stromal Cells, Multipotent Stem Cells, Peripheral Blood Stem Cell Transplantation, Reoperation, Stromal Cells, Transplantation, Homologous, Treatment Outcome",
author = "Ingo M{\"u}ller and Sandra Kordowich and Christina Holzwarth and Gesa Isensee and Peter Lang and Felix Neunhoeffer and Massimo Dominici and Johann Greil and Rupert Handgretinger",
year = "2007",
month = sep,
day = "18",
doi = "10.1016/j.bcmd.2007.06.021",
language = "English",
volume = "40",
pages = "25--32",
journal = "BLOOD CELL MOL DIS",
issn = "1079-9796",
publisher = "Academic Press Inc.",
number = "1",

}

RIS

TY - JOUR

T1 - Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation

AU - Müller, Ingo

AU - Kordowich, Sandra

AU - Holzwarth, Christina

AU - Isensee, Gesa

AU - Lang, Peter

AU - Neunhoeffer, Felix

AU - Dominici, Massimo

AU - Greil, Johann

AU - Handgretinger, Rupert

PY - 2007/9/18

Y1 - 2007/9/18

N2 - Multipotent mesenchymal stromal cells (MSC) have immunomodulatory effects. The aim of this study was to demonstrate safety and feasibility of MSC transfusion in pediatric patients who had undergone allogeneic stem cell transplantation from MMFD, MUD, MMUD and MSD. Patients with posttransplant complications based on deregulated immune effector cells who may benefit from an immunomodulatory effect of MSC had been selected. MSC were isolated from the hematopoietic stem cell donors in five cases and from a third party parental donor in two cases. We transfused ex vivo-expanded MSC in 11 doses into seven pediatric patients. Cell doses were escalated based on availability from 0.4x10(6) to 3.0x10(6) per kg bodyweight No adverse effects were detected with a maximum follow-up of 29 months. One out of three patients showed slight improvement of chronic GVHD. Two patients with severe acute GvHD did not progress to cGvHD. One patient received MSC to stabilize graft function after secondary haploidentical transplantation. One patient recovered from trilineage failure due to severe hemophagocytosis. This is the first case of a pediatric patient treated with MSC for trilineage failure after haploidentical stem cell transplantation from her father. We report the first series of 11 transfusions of expanded MSC in pediatric patients with immunological complications after allogeneic transplantation. Transfusion of MSC was safe and encouraging improvements in some patients were observed.

AB - Multipotent mesenchymal stromal cells (MSC) have immunomodulatory effects. The aim of this study was to demonstrate safety and feasibility of MSC transfusion in pediatric patients who had undergone allogeneic stem cell transplantation from MMFD, MUD, MMUD and MSD. Patients with posttransplant complications based on deregulated immune effector cells who may benefit from an immunomodulatory effect of MSC had been selected. MSC were isolated from the hematopoietic stem cell donors in five cases and from a third party parental donor in two cases. We transfused ex vivo-expanded MSC in 11 doses into seven pediatric patients. Cell doses were escalated based on availability from 0.4x10(6) to 3.0x10(6) per kg bodyweight No adverse effects were detected with a maximum follow-up of 29 months. One out of three patients showed slight improvement of chronic GVHD. Two patients with severe acute GvHD did not progress to cGvHD. One patient received MSC to stabilize graft function after secondary haploidentical transplantation. One patient recovered from trilineage failure due to severe hemophagocytosis. This is the first case of a pediatric patient treated with MSC for trilineage failure after haploidentical stem cell transplantation from her father. We report the first series of 11 transfusions of expanded MSC in pediatric patients with immunological complications after allogeneic transplantation. Transfusion of MSC was safe and encouraging improvements in some patients were observed.

KW - Adolescent

KW - Child

KW - Child, Preschool

KW - Female

KW - Graft Rejection

KW - Graft vs Host Disease

KW - Humans

KW - Male

KW - Mesenchymal Stem Cell Transplantation

KW - Mesenchymal Stromal Cells

KW - Multipotent Stem Cells

KW - Peripheral Blood Stem Cell Transplantation

KW - Reoperation

KW - Stromal Cells

KW - Transplantation, Homologous

KW - Treatment Outcome

U2 - 10.1016/j.bcmd.2007.06.021

DO - 10.1016/j.bcmd.2007.06.021

M3 - SCORING: Journal article

C2 - 17869550

VL - 40

SP - 25

EP - 32

JO - BLOOD CELL MOL DIS

JF - BLOOD CELL MOL DIS

SN - 1079-9796

IS - 1

ER -